Email this article 
Post a Comment Treatment of chronic viral hepatitis c in perm Krai
- Authors: Yakusheva M.V.1, Nebolsina A.P.1, Charushina I.P.1, Masalev V.V.1, Vorobyova N.N.2, Sumlyvaya O.N.2, Nikolenko V.V.2
-
Affiliations:
- Perm Regional Clinical Infectious Diseases Hospital
- E.A. Vagner Perm State Medical University
- Issue: Vol 40, No 6 (2023)
- Pages: 31-39
- Section: Original studies
- URL: https://bakhtiniada.ru/PMJ/article/view/254784
- DOI: https://doi.org/10.17816/pmj40631-39
- ID: 254784
Cite item
Full Text
Abstract
Objective. To analyze the effectiveness of etiotropic antiviral therapy with direct antiviral drugs against chronic viral hepatitis C in the adult population of the Perm Krai.
Materials and methods. In the regional register of Perm Krai, 20095 patients with chronic viral hepatitis C were registered. In 2019–2021, antiviral therapy with direct antiviral drugs, registered in the Russian Federation, and included in the list of vital and essential medicines for medical use was prescribed to 282 patients with chronic hepatitis C. There were 137 men (48.6 %), 145 (51.4 %) – women. The age of the patients ranged from 26 to 82 years, the duration of the disease – from 3 to 25 years.
Results. All the therapy regimes we used showed 100 % effectiveness in the population of patients suffering from chronic hepatitis C associated with mild liver fibrosis regardless of genotype, whereas in the population of patients with grade 3 fibrosis or liver cirrhosis, 100 % effectiveness was achieved only after the use of sofosbuvir-containing schemes. The pangenotypic schemes resulted in 100 % achievement of a stable virological response among patients with genotype 1 regardless of the stage of liver fibrosis and previous therapy experience. In the treatment of patients infected with genotype 3 of hepatitis C virus with severe fibrosis, the effectiveness of 100 % was noted after the use of sofosbuvir-containing regimes.
Conclusions. Among the adult population of Perm Krai, the overall effectiveness of therapy in patients with chronic hepatitis C, who used direct antiviral drugs, was 97.8 %.
Full Text
##article.viewOnOriginalSite##About the authors
M. V. Yakusheva
Perm Regional Clinical Infectious Diseases Hospital
Email: son-2005@yandex.ru
Candidate of Medical Sciences, Head of the Consultative and Diagnostic Department
Russian Federation, PermA. P. Nebolsina
Perm Regional Clinical Infectious Diseases Hospital
Email: son-2005@yandex.ru
Candidate of Medical Sciences, Deputy Chief Physician for Medical Activity
Russian Federation, PermI. P. Charushina
Perm Regional Clinical Infectious Diseases Hospital
Email: son-2005@yandex.ru
MD, PhD, Deputy Chief Physician for Organizational and Methodical Work
Russian Federation, PermV. V. Masalev
Perm Regional Clinical Infectious Diseases Hospital
Email: son-2005@yandex.ru
Candidate of Medical Sciences, Non-staff Chief Infectiologist of Perm Krai
Russian Federation, PermN. N. Vorobyova
E.A. Vagner Perm State Medical University
Email: son-2005@yandex.ru
MD, PhD, Professor, Head of the Department of Infectious Diseases
Russian Federation, PermO. N. Sumlyvaya
E.A. Vagner Perm State Medical University
Author for correspondence.
Email: son-2005@yandex.ru
MD, PhD, Professor, Department of Infectious Diseases
Russian Federation, PermV. V. Nikolenko
E.A. Vagner Perm State Medical University
Email: son-2005@yandex.ru
MD, PhD, Professor, Department of Infectious Diseases
Russian Federation, PermReferences
- Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis C and its outcomes in Russia: analysis of incidence, prevalence and mortality before the start of the infection elimination program. Infectious diseases 2018; 3: 37–45 (in Russian).
- Yushchuk N.D., Klimova E.A. Treatment of chronic hepatitis C in Russia: modern possibilities and immediate prospects. Infectious diseases: news, opinions, training 2017; 2: 86–95 (in Russian).
- Bhamidimarri K.R. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J. Hepatol. 2015; 63: 763765.
- Bourgeois S. et al. Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study. COGENT MEDICINE 2020; 7 (1).
- Castera L. Noninvasive evaluation of portal hypertension using transient elastography. J. Hepatol. 2012; 56 (3): 696–703.
- Chen T. et al. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. LiverInt. 2015; 35 (10): 2285–2293.
- Chung Feng Huang et al. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. J. Infect. Dis. 2019; 220 (4): 557–566.
- Di Bisceglie A.M. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J. Hepatol. 2005; 43: 434–441.
- EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020; 73 (5): 1170–1218.
- Eric Lawitz et al. Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial. Hepatology 2017; 65 (2): 439–450.
- Forns X., Lee S.S., Valdes J. et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 2017; 17: 1062–1068.
- Freiman J.M., Tran T.M., Schumacher S.G. et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virusinfection: a systematic review and metaanalysis. Ann Intern Med. 2016; 165: 345–355.
- Heidrich B., Pischke S., Helfritz F.A. et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J. Viral Hepat. 2014; 21: 769–779.
- Pol S. et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-monoinfected patients. J. Hepatol. 2017; 66 (1): 39–47.
- Saxena V. Safety and efficacy of sofosbuvir-containing regimens in hepatitis Cinfected patients with impaired renal function. Liver Int. 2016; 36: 807–816.
- Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211–221.
- Tarik Asselah et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: a randomized study. Liver Int. 2020; 40 (5): 1042–1051.
- Tarik Asselah et al. Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis. Liver Int. 2018; 38 (9): 1583–1591.
- WHO Global hepatitis report, 2018, available at: https://www.who.int/news-room/ factsheets/detail/hepatitis-C.
- Zohair A.U. Liver function tests in identifying patients with liver disease. ClinExp Gastroenterol. 2018; 11: 301–307.
Supplementary files
